From: Bendamustine in patients with relapsed or refractory multiple myeloma
 |  |  | Subgroups dosage |  | Subgroups therapy mode |  | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  |  | 80-100 mg/m 2 | 120-150 mg/m 2 |  | Monotherapy | + Steroids |  | ||||
n = 39 | Â | Â | n = 21 | n = 18 | p | n = 12 | n = 27 | p | ||||
PR | 14 (1 vgPR) | 36% | 7 | 33% | 7 | 38% | 0.8 | 3 | 25% | 11 | 40% | 0.5 |
MR | 7 | 18% | 4 | 19% | 3 | 17% | 1.0 | 2 | 17% | 5 | 19% | 1.0 |
SD | 10 | 26% | 7 | 33% | 3 | 17% | 0.3 | 5 | 42% | 5 | 19% | 0.2 |
PD | 8 | 20% | 3 | 15% | 5 | 28% | 0.4 | 2 | 17% | 6 | 22% | 1.0 |